FDG PET/MR诊断肝转移瘤:诊断准确性及技术流程的系统评价与Meta分析
8项研究进入诊断准确性合并分析,汇总敏感度0.94(95%CI 0.89-0.97)、特异度0.99(95%CI 0.92-1.00),敏感度存在明显研究间异质性(I²=0.83)。作者提出需规范采集协议与报告框架。
要点
- FDG PET/MR检出肝转移汇总敏感度0.94、特异度0.99,病变水平准确性高。
- 敏感度研究间异质性大(I²=0.83),特异度异质性低(I²=0.21)。
- PET采集、MR协议与重建参数报告不足且差异大,需标准化报告框架。
核心结论
- FDG PET/MR对肝转移瘤具有高汇总敏感度与特异度,但敏感度研究间变异大且技术参数常报告不全,需标准化采集与报告框架。
研究设计与样本
- 采用双变量随机效应模型合并敏感度与特异度,并对PET/MR采集、重建参数及判读策略进行结构化定性评估。
诊断标准与关键数值
- 肝转移瘤检出汇总敏感度0.94(95%CI 0.89-0.97),汇总特异度0.99(95%CI 0.92-1.00)。
- 敏感度异质性I²=0.83(显著),特异度异质性I²=0.21(低)。
临床应用与阅片要点
- 阅片与报告时应关注PET采集、MR序列、重建参数及运动校正是否充分披露,以利结果可复现与横向比较。
- 肝胆特异性对比剂仅在少数研究中使用,专用PET运动校正亦很少实施,解读相关文献结论时需注意这一技术差异。
局限性
- 纳入研究间PET采集、MR协议、重建参数与报告方式差异显著,体素大小、滤波及运动校正信息常报告不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This systematic review and meta-analysis evaluated the diagnostic performance of FDG PET/MR for detecting hepatic metastases from extrahepatic primary malignancies, together with acquisition protocols, reconstruction parameters, and technical heterogeneity.
METHODS: A systematic search was conducted through September 2026. Eligible studies evaluated FDG PET/MR for hepatic metastases and reported diagnostic performance data and/or technical protocol information. Summary estimates of sensitivity and specificity were obtained using a bivariate random-effects model. A structured qualitative assessment of PET and MR acquisition, reconstruction parameters, and image interpretation strategies was also performed.
RESULTS: Fifteen studies involving 861 patients met the inclusion criteria. Eight studies (53%) provided sufficient data for the diagnostic accuracy meta-analysis, whereas all contributed to the qualitative technical assessment. The meta-analysis demonstrated a summary sensitivity estimate of 0.94 (95% CI, 0.89-0.97) and a summary specificity estimate of 0.99 (95% CI, 0.92-1.00) for detecting hepatic metastases. Sensitivity showed substantial between-study heterogeneity (I² = 0.83), whereas specificity showed low heterogeneity (I² = 0.21). Technical assessment revealed marked variability in PET acquisition, MR protocols, reconstruction parameters, and reporting, with frequent underreporting of voxel size, filtering, and motion correction. Hepatobiliary contrast agents were used in only a minority of studies, and dedicated PET motion correction was rarely implemented.
CONCLUSION: FDG PET/MR demonstrates high lesion-level diagnostic accuracy for the detection of hepatic metastases, with high summary sensitivity and specificity. However, substantial between-study variability in sensitivity, together with variability and frequent underreporting of technical parameters, highlights the need for standardized acquisition protocols and reporting frameworks to improve reproducibility, comparability, and clinical translation.
引用
- Asmundo L, Steffani S, Zanardo M, et al. FDG PET/MR for liver metastases: a systematic review and meta-analysis of diagnostic accuracy and technical protocols with a proposed reporting framework. Abdom Radiol (NY). 2026. PMID: 42955096. doi:10.1007/s00261-026-05833-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。